Sanara Medtech INC 10-Q quarterly reports

Sanara MedTech Inc. (SMTI) filed its Form 10-Q for the quarter ended June 30, 2026, reporting increased net revenue and Adjusted EBITDA, alongside the significant announcement of a merger agreement with MiMedx Group, Inc.

Sanara MedTech Inc. announced a 19% increase in net revenue for Q1 2026, driven by strong performance in soft tissue repair products, and achieved net income from continuing operations.

Sanara MedTech reported significant revenue and gross profit growth in its continuing surgical operations for Q3 2025, alongside the strategic discontinuation and impairment of its Tissue Health Plus (THP) segment.

Sanara MedTech Inc. reports significant revenue growth in its surgical segment, alongside strategic investments in its new value-based wound care platform.

Sanara MedTech's Q1 2025 results show revenue growth driven by soft tissue repair products, alongside ongoing investments in Tissue Health Plus and strategic financial maneuvers.

Sanara MedTech Inc. saw a 35% increase in revenue year-over-year for the third quarter of 2024, driven by strong sales of soft tissue repair products.

Sanara MedTech Inc. reports a 28% increase in revenue for the second quarter of 2024, driven by strong sales of soft tissue repair products.

Sanara MedTech's first quarter of 2024 saw a 19% increase in revenue year-over-year, driven by strong sales in soft tissue repair products, while also navigating a change in CEO and a new debt facility.